—RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT

By afschroeder • July 19, 2025

DeFilipp Z, Choe HK, Efebera YA, Saad A, Farhan S, Lekakis LJ, Yared JA, Schiller GJ, Mapara MY, Assal A, Gooley TA, Bui JD, Lee DD, Lane H, Chen YB. ---RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT. Blood. 2025 Jul 18:blood.2025029584. doi: 10.1182/blood.2025029584. Epub ahead of print. PMID: 40680268.

Tags: Hematology/Oncology, Publications

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan[...]